List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5949699/publications.pdf

Version: 2024-02-01

357 papers	70,244 citations	1099 112 h-index	625 258 g-index
366 all docs	366 docs citations	366 times ranked	61196 citing authors

#	Article	IF	Citations
1	MicroRNA signatures in human cancers. Nature Reviews Cancer, 2006, 6, 857-866.	28.4	7,008
2	A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2257-2261.	7.1	5,220
3	MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research, 2005, 65, 7065-7070.	0.9	3,719
4	MicroRNAs in Cancer. Annual Review of Medicine, 2009, 60, 167-179.	12.2	1,702
5	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15805-15810.	7.1	1,538
6	MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma. JAMA - Journal of the American Medical Association, 2008, 299, 425-36.	7.4	1,386
7	MicroRNA Signatures in Human Ovarian Cancer. Cancer Research, 2007, 67, 8699-8707.	0.9	1,356
8	Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis. Cancer Cell, 2014, 26, 707-721.	16.8	1,293
9	MicroRNAs in body fluidsâ€"the mix of hormones and biomarkers. Nature Reviews Clinical Oncology, 2011, 8, 467-477.	27.6	1,290
10	miRNAs, Cancer, and Stem Cell Division. Cell, 2005, 122, 6-7.	28.9	1,271
11	MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nature Reviews Drug Discovery, 2013, 12, 847-865.	46.4	1,234
12	The role of microRNA genes in papillary thyroid carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 19075-19080.	7.1	1,137
13	A MicroRNA Signature of Hypoxia. Molecular and Cellular Biology, 2007, 27, 1859-1867.	2.3	990
14	A microRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13556-13561.	7.1	990
15	Clinical relevance of circulating cell-free microRNAs in cancer. Nature Reviews Clinical Oncology, 2014, 11, 145-156.	27.6	915
16	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. Cancer Research, 2007, 67, 6092-6099.	0.9	782
17	Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncology, The, 2010, 11, 136-146.	10.7	752
18	Noncoding RNA therapeutics â€" challenges and potential solutions. Nature Reviews Drug Discovery, 2021, 20, 629-651.	46.4	749

#	Article	IF	Citations
19	MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5166-5171.	7.1	741
20	MicroRNAs â€" the micro steering wheel of tumour metastases. Nature Reviews Cancer, 2009, 9, 293-302.	28.4	740
21	RNA interference in the clinic: challenges and future directions. Nature Reviews Cancer, 2011, 11, 59-67.	28.4	729
22	MicroRNA expression and function in cancer. Trends in Molecular Medicine, 2006, 12, 580-587.	6.7	699
23	Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas. Cancer Cell, 2007, 12, 215-229.	16.8	681
24	Genomic Profiling of MicroRNA and Messenger RNA Reveals Deregulated MicroRNA Expression in Prostate Cancer. Cancer Research, 2008, 68, 6162-6170.	0.9	661
25	Long Noncoding RNA in Prostate, Bladder, and Kidney Cancer. European Urology, 2014, 65, 1140-1151.	1.9	601
26	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood, 2008, 111, 3183-3189.	1.4	575
27	Tcl1 Expression in Chronic Lymphocytic Leukemia Is Regulated by miR-29 and miR-181. Cancer Research, 2006, 66, 11590-11593.	0.9	568
28	Micro-RNA profiling in kidney and bladder cancers. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 387-392.	1.6	566
29	miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery, 2016, 6, 235-246.	9.4	554
30	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	5.5	526
31	miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts. Cell, 2010, 140, 652-665.	28.9	514
32	PDL1 Regulation by p53 via miR-34. Journal of the National Cancer Institute, 2016, 108, .	6.3	475
33	CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2750-2755.	7.1	473
34	PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology, 2016, 18, 195-205.	1.2	463
35	Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 OncogeneÂExpression. Cancer Cell, 2008, 13, 496-506.	16.8	459
36	MicroRNAome genome: A treasure for cancer diagnosis and therapy. Ca-A Cancer Journal for Clinicians, 2014, 64, 311-336.	329.8	428

#	Article	IF	Citations
37	MicroRNA 29b functions in acute myeloid leukemia. Blood, 2009, 114, 5331-5341.	1.4	412
38	The multiMiR R package and database: integration of microRNAâ€“target interactions along with their disease and drug associations. Nucleic Acids Research, 2014, 42, e133-e133.	14.5	409
39	MicroRNA fingerprints during human megakaryocytopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5078-5083.	7.1	403
40	miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy. Clinical Cancer Research, 2009, 15, 5060-5072.	7.0	386
41	Data Normalization Strategies for MicroRNA Quantification. Clinical Chemistry, 2015, 61, 1333-1342.	3.2	384
42	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1106-15.	7.1	376
43	Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility. Cancer Research, 2010, 70, 2789-2798.	0.9	365
44	Tumour angiogenesis regulation by the miR-200 family. Nature Communications, 2013, 4, 2427.	12.8	363
45	microRNA Therapeutics in Cancer â€" An Emerging Concept. EBioMedicine, 2016, 12, 34-42.	6.1	360
46	A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nature Genetics, 2009, 41, 365-370.	21.4	355
47	Clinical utility of circulating non-coding RNAs â€" an update. Nature Reviews Clinical Oncology, 2018, 15, 541-563.	27.6	353
48	MicroRNA history: Discovery, recent applications, and next frontiers. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 717, 1-8.	1.0	351
49	Regulation of Tumor Angiogenesis by EZH2. Cancer Cell, 2010, 18, 185-197.	16.8	346
50	Reprogramming of miRNA networks in cancer and leukemia. Genome Research, 2010, 20, 589-599.	5.5	331
51	MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. Molecular Aspects of Medicine, 2019, 70, 3-20.	6.4	307
52	A Genetic Defect in Exportin-5 Traps Precursor MicroRNAs in the Nucleus of Cancer Cells. Cancer Cell, 2010, 18, 303-315.	16.8	299
53	Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	298
54	MicroRNA Fingerprints Identify miR-150 as a Plasma Prognostic Marker in Patients with Sepsis. PLoS ONE, 2009, 4, e7405.	2.5	273

#	Article	IF	Citations
55	Cellâ€toâ€cell communication: microRNAs as hormones. Molecular Oncology, 2017, 11, 1673-1686.	4.6	267
56	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 2012, 118, 2603-2614.	4.1	265
57	Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. JAMA - Journal of the American Medical Association, 2011, 305, 59.	7.4	256
58	An Integrated Approach for Experimental Target Identification of Hypoxia-induced miR-210. Journal of Biological Chemistry, 2009, 284, 35134-35143.	3.4	248
59	The Potential of MicroRNAs as Prostate Cancer Biomarkers. European Urology, 2016, 70, 312-322.	1.9	243
60	Loss of p53 drives neuron reprogramming in head and neck cancer. Nature, 2020, 578, 449-454.	27.8	241
61	mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Molecular Cancer, 2007, 6, 54.	19.2	240
62	MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer. Cancer Research, 2009, 69, 9090-9095.	0.9	229
63	PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8403-8408.	7.1	226
64	SnapShot: MicroRNAs in Cancer. Cell, 2009, 137, 586-586.e1.	28.9	223
65	miR-124 Inhibits STAT3 Signaling to Enhance T Cellâ€“Mediated Immune Clearance of Glioma. Cancer Research, 2013, 73, 3913-3926.	0.9	223
66	Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4394-4399.	7.1	222
67	MicroRNAs and cancerâ€”new paradigms in molecular oncology. Current Opinion in Cell Biology, 2009, 21, 470-479.	5.4	219
68	RNAi Therapies: Drugging the Undruggable. Science Translational Medicine, 2014, 6, 240ps7.	12.4	215
69	Low frequency of alterations of the Î± (PPP2R1A) and Î² (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene, 2000, 19, 1191-1195.	5.9	206
70	Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nature Cell Biology, 2015, 17, 311-321.	10.3	205
71	Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas. Journal of Cellular Physiology, 2007, 210, 370-377.	4.1	203
72	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood, 2010, 116, 945-952.	1.4	200

#	Article	IF	Citations
73	The fusion of two worlds: Non-coding RNAs and extracellular vesicles - diagnostic and therapeutic implications (Review). International Journal of Oncology, 2015, 46, 17-27.	3.3	192
74	A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients. Clinical Cancer Research, 2015, 21, 1207-1214.	7.0	191
75	Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood, 2013, 122, 1891-1899.	1.4	184
76	MicroRNAs and cancer: Profile, profile, profile. International Journal of Cancer, 2008, 122, 969-977.	5.1	182
77	Strand-Specific miR-28-5p and miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. Gastroenterology, 2012, 142, 886-896.e9.	1.3	174
78	Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer. Molecular Therapy, 2014, 22, 1494-1503.	8.2	172
79	MicroRNAs. Cancer Journal (Sudbury, Mass), 2008, 14, 1-6.	2.0	171
80	CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget, 2013, 4, 1748-1762.	1.8	169
81	Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587. Cancer Research, 2017, 77, 5808-5819.	0.9	169
82	Progresses towards safe and efficient gene therapy vectors. Oncotarget, 2015, 6, 30675-30703.	1.8	163
83	MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood, 2014, 124, 546-554.	1.4	162
84	MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology, 2016, 18, 639-648.	1.2	161
85	Epigenetics and miRNAs in Human Cancer. Advances in Genetics, 2010, 70, 87-99.	1.8	160
86	Targeting microRNAs as key modulators of tumor immune response. Journal of Experimental and Clinical Cancer Research, 2016, 35, 103.	8.6	160
87	Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine, 2018, 38, 100-112.	6.1	159
88	Prooncogenic Factors miR-23b and miR-27b Are Regulated by Her2/Neu, EGF, and TNF-Î± in Breast Cancer. Cancer Research, 2013, 73, 2884-2896.	0.9	158
89	Cell-to-cell miRNA transfer: From body homeostasis to therapy. , 2012, 136, 169-174.		156
90	miRâ€203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Molecular Oncology, 2014, 8, 83-92.	4.6	156

#	Article	IF	Citations
91	Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step. EMBO Journal, 2013, 32, 2672-2684.	7.8	152
92	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. Cell, 2019, 177, 231-242.	28.9	152
93	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications, 2014, 5, 5202.	12.8	151
94	Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. Journal of Clinical Investigation, 2007, 117, 2059-2066.	8.2	151
95	Regulatory mechanisms of microRNAs involvement in cancer. Expert Opinion on Biological Therapy, 2007, 7, 1009-1019.	3.1	150
96	MicroRNA profiling in cancer. Clinical Science, 2011, 121, 141-158.	4.3	150
97	MicroRNA Processing and Human Cancer. Journal of Clinical Medicine, 2015, 4, 1651-1667.	2.4	150
98	Exosomal lncRNAs as new players in cell-to-cell communication. Translational Cancer Research, 2018, 7, S243-S252.	1.0	150
99	Small molecule compounds targeting miRNAs for cancer therapy. Advanced Drug Delivery Reviews, 2015, 81, 104-116.	13.7	142
100	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Molecular Cell, 2016, 61, 520-534.	9.7	142
101	Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. Cancer Discovery, 2013, 3, 1302-1315.	9.4	140
102	MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8017-8022.	7.1	138
103	Regulation of pri-miRNA Processing by a Long Noncoding RNA Transcribed from an Ultraconserved Region. Molecular Cell, 2014, 55, 138-147.	9.7	137
104	Cancer Hallmarks and MicroRNAs: The Therapeutic Connection. Advances in Cancer Research, 2017, 135, 119-149.	5.0	135
105	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget, 2015, 6, 37269-37280.	1.8	135
106	Expression of microRNAs and proteinâ€coding genes associated with perineural invasion in prostate cancer. Prostate, 2008, 68, 1152-1164.	2.3	134
107	Regulation of microRNA Expression: the Hypoxic Component. Cell Cycle, 2007, 6, 1425-1430.	2.6	132
108	Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood, 2009, 113, 5568-5574.	1.4	129

#	Article	IF	Citations
109	Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome. Epigenetics, 2010, 5, 656-663.	2.7	125
110	RNAi-based therapeutics and tumor targeted delivery in cancer. Advanced Drug Delivery Reviews, 2022, 182, 114113.	13.7	123
111	miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Review of Molecular Diagnostics, 2013, 13, 183-204.	3.1	122
112	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 2017, 23, 2891-2904.	7.0	122
113	A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO Journal, 2013, 32, 2833-2847.	7.8	120
114	The Clinical Relevance of Long Non-Coding RNAs in Cancer. Cancers, 2015, 7, 2169-2182.	3.7	120
115	Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Research, 2016, 76, 7194-7207.	0.9	118
116	Circular RNAs in Cancer â€“ Lessons Learned From microRNAs. Frontiers in Oncology, 2018, 8, 179.	2.8	115
117	Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduction and Targeted Therapy, 2022, 7, 121.	17.1	114
118	Effect of miR-142-3p on the M2 Macrophage and Therapeutic Efficacy Against Murine Glioblastoma. Journal of the National Cancer Institute, 2014, 106, .	6.3	112
119	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut, 2016, 65, 977-989.	12.1	111
120	An miR-502â€“Binding Site Single-Nucleotide Polymorphism in the 3â€²-Untranslated Region of the SET8 Gene Is Associated with Early Age of Breast Cancer Onset. Clinical Cancer Research, 2009, 15, 6292-6300.	7.0	106
121	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-Î²-Catenin Signaling in Colorectal Cancer. EBioMedicine, 2016, 13, 113-124.	6.1	106
122	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports, 2015, 13, 2395-2402.	6.4	105
123	Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes and Cancer, 2019, 58, 244-253.	2.8	105
124	Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Scientific Reports, 2013, 3, 2687.	3.3	104
125	HypoxamiRs and Cancer: From Biology to Targeted Therapy. Antioxidants and Redox Signaling, 2014, 21, 1220-1238.	5.4	102
126	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood, 2011, 118, 413-415.	1.4	101

#	Article	IF	Citations
127	Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of Genistein. Nutrition and Cancer, 2016, 68, 154-164.	2.0	101
128	Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood, 2009, 114, 4761-4770.	1.4	100
129	Molecular Pathways: microRNAs, Cancer Cells, and Microenvironment. Clinical Cancer Research, 2014, 20, 6247-6253.	7.0	99
130	Noncoding <scp>RNA</scp>s and immune checkpointsâ€"clinical implications as cancer therapeutics. FEBS Journal, 2017, 284, 1952-1966.	4.7	99
131	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology, 2017, 18, 98.	8.8	97
132	The Interaction Between Two Worlds: MicroRNAs and Toll-Like Receptors. Frontiers in Immunology, 2019, 10, 1053.	4.8	95
133	Classical and noncanonical functions of miRNAs in cancers. Trends in Genetics, 2022, 38, 379-394.	6.7	94
134	Decrypting noncoding RNA interactions, structures, and functional networks. Genome Research, 2019, 29, 1377-1388.	5.5	93
135	Expression, Tissue Distribution and Function of miR-21 in Esophageal Squamous Cell Carcinoma. PLoS ONE, 2013, 8, e73009.	2.5	93
136	MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Medicine, 2011, 3, 56.	8.2	92
137	MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology, 2011, 54, 2089-2098.	7.3	91
138	High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer. PLoS ONE, 2014, 9, e83113.	2.5	91
139	Clinically Relevant microRNAs in Ovarian Cancer. Molecular Cancer Research, 2015, 13, 393-401.	3.4	90
140	RNA-Binding Proteins as Important Regulators of Long Non-Coding RNAs in Cancer. International Journal of Molecular Sciences, 2020, 21, 2969.	4.1	89
141	The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Practice and Research in Clinical Haematology, 2007, 20, 425-437.	1.7	87
142	Non-coding RNAs regulation of macrophage polarization in cancer. Molecular Cancer, 2021, 20, 24.	19.2	86
143	Regulation of microRNA expression: the hypoxic component. Cell Cycle, 2007, 6, 1426-31.	2.6	86
144	Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood, 2009, 113, 3744-3753.	1.4	85

#	Article	IF	Citations
145	The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenvironment, 2010, 3, 137-147.	3.1	85
146	Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk. Cancer Research, 2021, 81, 1431-1440.	0.9	84
147	Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene, 2015, 34, 1619-1628.	5.9	82
148	MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget, 2017, 8, 11641-11658.	1.8	81
149	MicroRNA based theranostics for brain cancer: basic principles. Journal of Experimental and Clinical Cancer Research, 2019, 38, 231.	8.6	81
150	GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cellular Signalling, 2020, 68, 109539.	3.6	81
151	<scp>MicroRNAs</scp> as therapeutic targets in human cancers. Wiley Interdisciplinary Reviews RNA, 2014, 5, 537-548.	6.4	80
152	Epigenetic Regulation of miRNAs in Cancer. Advances in Experimental Medicine and Biology, 2013, 754, 137-148.	1.6	79
153	Cross Talk Between MicroRNA and Coding Cancer Genes. Cancer Journal (Sudbury, Mass), 2012, 18, 223-231.	2.0	77
154	Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer. International Journal of Molecular Sciences, 2017, 18, 473.	4.1	77
155	Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. Non-coding RNA, 2015, 1, 53-68.	2.6	76
156	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports, 2016, 15, 1493-1504.	6.4	75
157	Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. Molecular Carcinogenesis, 2018, 57, 137-141.	2.7	75
158	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology, 2020, 159, 2146-2162.e33.	1.3	75
159	MicroRNAs: Fundamental facts and involvement in human diseases. Birth Defects Research Part C: Embryo Today Reviews, 2006, 78, 180-189.	3.6	74
160	A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocrine-Related Cancer, 2013, 20, 809-823.	3.1	74
161	Using microRNA Networks to Understand Cancer. International Journal of Molecular Sciences, 2018, 19, 1871.	4.1	74
162	Examining plasma microRNA markers for colorectal cancer at different stages. Oncotarget, 2016, 7, 11434-11449.	1.8	74

#	Article	IF	Citations
163	Functional relevance of miRNA* sequences in human disease. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2012, 731, 14-19.	1.0	72
164	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. Journal of the National Cancer Institute, 2016, 108, djw026.	6.3	70
165	Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis, 2010, 31, 208-215.	2.8	68
166	Non-coding RNAs: Identification of Cancer-Associated microRNAs by Gene Profiling. Technology in Cancer Research and Treatment, 2010, 9, 123-138.	1.9	67
167	Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients. Clinical Cancer Research, 2012, 18, 3982-3991.	7.0	67
168	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NFÎºB pathway. Molecular Cancer, 2013, 12, 173.	19.2	66
169	Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. Oncotarget, 2016, 7, 20636-20654.	1.8	66
170	Cancer-associated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications. Mammalian Genome, 2008, 19, 526-40.	2.2	65
171	Complex Patterns of Altered MicroRNA Expression during the Adenoma-Adenocarcinoma Sequence for Microsatellite-Stable Colorectal Cancer. Clinical Cancer Research, 2011, 17, 7283-7293.	7.0	65
172	Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. Clinical Cancer Research, 2018, 24, 4225-4241.	7.0	64
173	MicroRNAs in the ontogeny of leukemias and lymphomas. Leukemia and Lymphoma, 2009, 50, 160-170.	1.3	63
174	Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. Molecular Cancer, 2013, 12, 13.	19.2	63
175	In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. Molecular Therapy - Nucleic Acids, 2015, 4, e270.	5.1	63
176	MiR-181 family-specific behavior in different cancers: a meta-analysis view. Cancer and Metastasis Reviews, 2018, 37, 17-32.	5.9	63
177	Current Status of Long Non-Coding RNAs in Human Breast Cancer. International Journal of Molecular Sciences, 2016, 17, 1485.	4.1	62
178	A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nature Communications, 2018, 9, 461.	12.8	61
179	Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget, 2016, 7, 15093-15104.	1.8	61
180	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clinical Cancer Research, 2015, 21, 2127-2137.	7.0	60

#	Article	IF	Citations
181	Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Breast Cancer Research and Treatment, 2018, 171, 593-605.	2.5	60
182	Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. PLoS ONE, 2012, 7, e41170.	2.5	59
183	Non-coding RNAs: the cancer genome dark matter that matters!. Clinical Chemistry and Laboratory Medicine, 2017, 55, 705-714.	2.3	58
184	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Research, 2018, 28, 432-447.	5.5	58
185	NCRNA Combined Therapy as Future Treatment Option for Cancer. Current Pharmaceutical Design, 2014, 20, 6565-6574.	1.9	58
186	MicroRNAs, Regulatory Messengers Inside and Outside Cancer Cells. Advances in Experimental Medicine and Biology, 2018, 1056, 87-108.	1.6	57
187	Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Molecular Cancer, 2013, 12, 50.	19.2	56
188	Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget, 2017, 8, 20145-20164.	1.8	56
189	MALAT1 promoted invasiveness of gastric adenocarcinoma. BMC Cancer, 2017, 17, 46.	2.6	54
190	MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. Endocrine-Related Cancer, 2010, 17, F51-F75.	3.1	53
191	Non-coding RNAs as theranostics in human cancers. Journal of Cellular Biochemistry, 2011, 113, n/a-n/a.	2.6	52
192	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. Clinical Cancer Research, 2014, 20, 4141-4153.	7.0	52
193	MicroRNAs and ceRNAs: therapeutic implications of RNA networks. Expert Opinion on Biological Therapy, 2014, 14, 1285-1293.	3.1	52
194	Genetic and epigenetic alterations of micro<scp>RNA</scp>s and implications for human cancers and other diseases. Genes Chromosomes and Cancer, 2016, 55, 193-214.	2.8	52
195	MicroRNAs and Cancer Therapy â€“ From Bystanders to Major Players. Current Medicinal Chemistry, 2013, 20, 3561-3573.	2.4	50
196	Key principles of miRNA involvement in human diseases. Discoveries, 2014, 2, e34.	2.3	50
197	miR-195 inhibits macrophages pro-inflammatory profile and impacts the crosstalk with smooth muscle cells. PLoS ONE, 2017, 12, e0188530.	2.5	49
198	MiR-200 family and cancer: From a meta-analysis view. Molecular Aspects of Medicine, 2019, 70, 57-71.	6.4	49

#	Article	IF	Citations
199	The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications, 2015, 6, 7351.	12.8	48
200	To Wnt or Lose: The Missing Non-Coding Linc in Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 2003.	4.1	48
201	A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular RNAs. Frontiers in Cell and Developmental Biology, 2020, 8, 50.	3.7	48
202	Non-coding RNAs and ferroptosis: potential implications for cancer therapy. Cell Death and Differentiation, 2022, 29, 1094-1106.	11.2	48
203	From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies. Frontiers in Oncology, 2015, 5, 21.	2.8	47
204	MicroRNAs, ultraconserved genes and colorectal cancers. International Journal of Biochemistry and Cell Biology, 2010, 42, 1291-1297.	2.8	46
205	Novel Insights of Structure-Based Modeling for RNA-Targeted Drug Discovery. Journal of Chemical Information and Modeling, 2012, 52, 2741-2753.	5.4	46
206	The Mix of Two Worlds: Non-Coding RNAs and Hormones. Nucleic Acid Therapeutics, 2013, 23, 2-8.	3.6	45
207	The Many Faces of Long Noncoding RNAs in Cancer. Antioxidants and Redox Signaling, 2018, 29, 922-935.	5.4	45
208	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 2016, 7, 31361-31371.	1.8	45
209	Coordinated Targeting of the EGFR Signaling Axis by MicroRNA-27a*. Oncotarget, 2013, 4, 1388-1398.	1.8	44
210	Epsteinâ€“Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine, 2015, 2, 572-582.	6.1	43
211	Overexpression of miR-125a in Myelodysplastic Syndrome CD34+ Cells Modulates NF-ÎºB Activation and Enhances Erythroid Differentiation Arrest. PLoS ONE, 2014, 9, e93404.	2.5	42
212	MicroRNAs and Ultraconserved Genes as Diagnostic Markers and Therapeutic Targets in Cancer and Cardiovascular Diseases. Journal of Cardiovascular Translational Research, 2010, 3, 271-279.	2.4	41
213	MicroRNAs in cancer therapeutics: â€œfrom the bench to the bedsideâ€• Expert Opinion on Biological Therapy, 2015, 15, 1381-1385.	3.1	40
214	MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods. Cancers, 2020, 12, 2009.	3.7	40
215	Synchronous down-modulation of miR-17 family members is an early causative event in the retinal angiogenic switch. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3770-3775.	7.1	39
216	Ultraconserved long non-coding RNA uc.63 in breast cancer. Oncotarget, 2017, 8, 35669-35680.	1.8	38

#	Article	IF	Citations
217	The role of a new class of long noncoding RNAs transcribed from ultraconserved regions in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 449-455.	7.4	37
218	MicroRNAs and Long Non-Coding RNAs and Their Hormone-Like Activities in Cancer. Cancers, 2019, 11, 378.	3.7	37
219	Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. Oncotarget, 2016, 7, 53165-53177.	1.8	37
220	Non-coding RNAs and cancer: new paradigms in oncology. Discovery Medicine, 2011, 11, 245-54.	0.5	37
221	Targeting the microRNA-regulating DNA damage/repair pathways in cancer. Expert Opinion on Biological Therapy, 2014, 14, 1667-1683.	3.1	36
222	Regulation of hnRNPA1 by microRNAs controls the miR-18aâ€“K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discovery, 2017, 3, 17029.	6.7	36
223	Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. Nature Communications, 2017, 8, 1801.	12.8	36
224	Key questions about the checkpoint blockade-are microRNAs an answer?. Cancer Biology and Medicine, 2018, 15, 103.	3.0	36
225	Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma. Cancers, 2019, 11, 1580.	3.7	36
226	Non-Coding RNAs in IGF-1R Signaling Regulation: The Underlying Pathophysiological Link between Diabetes and Cancer. Cells, 2019, 8, 1638.	4.1	36
227	Roles and clinical implications of microRNAs in acute lymphoblastic leukemia. Journal of Cellular Physiology, 2018, 233, 5642-5654.	4.1	35
228	Long Non-coding RNAs in Myeloid Malignancies. Frontiers in Oncology, 2019, 9, 1048.	2.8	35
229	Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. Oncotarget, 2015, 6, 7262-7279.	1.8	35
230	MicroRNA and Epigenetics: Diagnostic and Therapeutic Opportunities. Current Pathobiology Reports, 2013, 1, 43-52.	3.4	34
231	FuncPEP: A Database of Functional Peptides Encoded by Non-Coding RNAs. Non-coding RNA, 2020, 6, 41.	2.6	34
232	GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGFÎ² effectors, Drosha and microRNAs with opposite oncogenic potentials. Nucleic Acids Research, 2010, 38, 7673-7688.	14.5	32
233	A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma. Genome Medicine, 2014, 6, 76.	8.2	32
234	The protein phosphatase 2A regulatory subunit B55Î± is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1969-1977.	4.1	32

#	Article	IF	Citations
235	MicroRNAs and genomic variations: from Proteus tricks to Prometheus gift. Carcinogenesis, 2009, 30, 912-917.	2.8	31
236	Signal Transducer and Activator of Transcriptionâ€“3 Induces MicroRNA-155 Expression in Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e64678.	2.5	31
237	MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?. Seminars in Oncology, 2016, 43, 209-214.	2.2	31
238	Metformin blocks <scp>MYC</scp> protein synthesis in colorectal cancer via m<scp>TOR</scp>â€4<scp>EBP</scp>â€e<scp>IF</scp>4E and MNK1â€e<scp>IF</scp>4Gâ€e<scp>IF</scp>4E signaling. Molecular Oncology, 2018, 12, 1856-1870.	4.6	31
239	Editing and Chemical Modifications on Non-Coding RNAs in Cancer: A New Tale with Clinical Significance. International Journal of Molecular Sciences, 2021, 22, 581.	4.1	31
240	Circulating miRNAs in sepsisâ€”A network under attack: An in-silico prediction of the potential existence of miRNA sponges in sepsis. PLoS ONE, 2017, 12, e0183334.	2.5	31
241	RNA Inhibition, MicroRNAs, and New Therapeutic Agents for Cancer Treatment. Clinical Lymphoma and Myeloma, 2009, 9, S313-S318.	1.4	30
242	MicroRNAs: Toward the Clinic for Breast Cancer Patients. Seminars in Oncology, 2011, 38, 764-775.	2.2	30
243	Circulating microRNAs as Promising Tumor Biomarkers. Advances in Clinical Chemistry, 2014, 67, 189-214.	3.7	30
244	Inflamma-miRs in Aging and Breast Cancer: Are They Reliable Players?. Frontiers in Medicine, 2015, 2, 85.	2.6	30
245	Interplay between epigenetic abnormalities and deregulated expression of microRNAs in cancer. Seminars in Cancer Biology, 2019, 58, 47-55.	9.6	30
246	Clinical significance of the interaction between non-coding RNAs and the epigenetics machinery. Epigenetics, 2014, 9, 75-80.	2.7	29
247	Understanding the Genomic Ultraconservations: T-UCRs and Cancer. International Review of Cell and Molecular Biology, 2017, 333, 159-172.	3.2	29
248	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. British Journal of Cancer, 2019, 120, 340-345.	6.4	29
249	Principles of microRNA involvement in human cancers. Chinese Journal of Cancer, 2011, 30, 739-748.	4.9	29
250	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Modern Pathology, 2015, 28, 373-382.	5.5	28
251	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clinical Cancer Research, 2016, 22, 2359-2367.	7.0	28
252	Long nonâ€coding RNA uc.291 controls epithelial differentiation by interfering with the ACTL6A/BAF complex. EMBO Reports, 2020, 21, e46734.	4.5	28

#	Article	IF	Citations
253	A mathematical model for the quantification of a patientâ€™s sensitivity to checkpoint inhibitors and long-term tumour burden. Nature Biomedical Engineering, 2021, 5, 297-308.	22.5	28
254	Non-coding RNAs for Medical Practice in Oncology. Keio Journal of Medicine, 2011, 60, 106-113.	1.1	27
255	lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System. Cancers, 2020, 12, 2148.	3.7	27
256	MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44. Scientific Reports, 2021, 11, 9219.	3.3	26
257	Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. Haematologica, 2018, 103, 2069-2078.	3.5	25
258	Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs. Seminars in Cancer Biology, 2022, 83, 197-207.	9.6	25
259	miRNA as Potential Biomarkers of Breast Cancer in the Lebanese Population and in Young Women: A Pilot Study. PLoS ONE, 2014, 9, e107566.	2.5	25
260	The role of exosomal long non-coding RNAs in cancer drug resistance. , 2019, 2, 1178-1192.		25
261	Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. International Journal of Oncology, 2011, 38, 1153-61.	3.3	24
262	Hematopoietic stem cells from induced pluripotent stem cells â€“ considering the role of microRNA as a cell differentiation regulator. Journal of Cell Science, 2018, 131, .	2.0	24
263	The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. Molecular Therapy - Nucleic Acids, 2019, 14, 301-317.	5.1	24
264	Therapeutic Potential of the miRNAâ€“ATM Axis in the Management of Tumor Radioresistance. Cancer Research, 2020, 80, 139-150.	0.9	24
265	OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Scientific Reports, 2018, 8, 13106.	3.3	23
266	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. Clinical Epigenetics, 2019, 11, 71.	4.1	23
267	microRNA Expression in Ethnic Specific Early Stage Breast Cancer: an Integration and Comparative Analysis. Scientific Reports, 2017, 7, 16829.	3.3	22
268	Long non-coding RNAs within the tumour microenvironment and their role in tumour-stroma cross-talk. Cancer Letters, 2018, 421, 94-102.	7.2	22
269	Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. RNA Biology, 2020, 17, 1523-1534.	3.1	22
270	Circulating Non-coding RNAs in Renal Cell Carcinomaâ€”Pathogenesis and Potential Implications as Clinical Biomarkers. Frontiers in Cell and Developmental Biology, 2020, 8, 828.	3.7	22

#	Article	IF	Citations
271	Design of a miRNA sponge for the miR-17 miRNA family as a therapeutic strategy against vulvar carcinoma. Molecular and Cellular Probes, 2015, 29, 420-426.	2.1	21
272	miR-122 and hepatocellular carcinoma: from molecular biology to therapeutics. EBioMedicine, 2018, 37, 17-18.	6.1	21
273	Long non-coding RNA CCAT2 as a therapeutic target in colorectal cancer. Expert Opinion on Therapeutic Targets, 2018, 22, 973-976.	3.4	20
274	The involvement of microRNA in the pathogenesis of Richter syndrome. Haematologica, 2019, 104, 1004-1015.	3.5	20
275	The Interplay between MicroRNAs and the Components of the Tumor Microenvironment in B-Cell Malignancies. International Journal of Molecular Sciences, 2020, 21, 3387.	4.1	20
276	microRNA-10b: A New Marker or the Marker of Pancreatic Ductal Adenocarcinoma?. Clinical Cancer Research, 2011, 17, 5527-5529.	7.0	19
277	MicroRNAs as Main Players in the Pathogenesis of Chronic Lymphocytic Leukemia. MicroRNA (Shariqah,) Tj ETQq1 1 0.784314 rgBT /O	1.2	19
278	Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections. EBioMedicine, 2017, 20, 182-192.	6.1	19
279	Integrated MicroRNAâ€“mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 194.	4.1	18
280	miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight, 2020, 5, .	5.0	18
281	Patients After Splenectomy: Old Risks and New Perspectives. Chirurgia (Romania), 2016, 111, 393.	0.5	18
282	Tracking miRNAs' footprints in tumorâ€“microenvironment interactions: Insights and implications for targeted cancer therapy. Genes Chromosomes and Cancer, 2015, 54, 335-352.	2.8	17
283	The nonâ€coding RNome after splenectomy. Journal of Cellular and Molecular Medicine, 2019, 23, 7844-7858.	3.6	17
284	Highlighting transcribed ultraconserved regions in human diseases. Wiley Interdisciplinary Reviews RNA, 2020, 11, e1567.	6.4	17
285	Epigenetically regulated microRNAs and their prospect in cancer diagnosis. Expert Review of Molecular Diagnostics, 2014, 14, 673-683.	3.1	16
286	A Multiscale Agent-Based Model of Ductal CarcinomaIn Situ. IEEE Transactions on Biomedical Engineering, 2020, 67, 1450-1461.	4.2	16
287	targetHub: a programmable interface for miRNAâ€“gene interactions. Bioinformatics, 2013, 29, 2657-2658.	4.1	14
288	From mobility to crosstalk. A model of intracellular miRNAs motion may explain the RNAs interaction mechanism on the basis of target subcellular localization. Mathematical Biosciences, 2016, 280, 50-61.	1.9	14

#	Article	IF	Citations
289	Expression profiles of micro RNA in proliferating and differentiating 32D murine myeloid cells. Journal of Cellular Physiology, 2006, 207, 706-710.	4.1	13
290	microRNA and Chronic Lymphocytic Leukemia. Advances in Experimental Medicine and Biology, 2015, 889, 23-40.	1.6	12
291	Non-Coding RNAs as Cancer Hallmarks in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences, 2020, 21, 6720.	4.1	12
292	Frequent methylation of the tumour suppressor miRâ€1258 targeting PDL1: implication in multiple myelomaâ€specific cytotoxicity and prognostification. British Journal of Haematology, 2020, 190, 249-261.	2.5	12
293	Subcellular Localization of uc.8+ as a Prognostic Biomarker in Bladder Cancer Tissue. Cancers, 2021, 13, 681.	3.7	12
294	Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer. Pharmaceutical Research, 2022, 39, 511-528.	3.5	12
295	MicroRNAs: Clinical Trials and Potential Applications. Clinical Journal of Oncology Nursing, 2017, 21, 554-559.	0.6	11
296	Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy. Clinical Epigenetics, 2020, 12, 150.	4.1	11
297	Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination. Cancer Cell International, 2020, 20, 403.	4.1	11
298	Fractal-like kinetics of intracellular enzymatic reactions: a chemical framework of endotoxin tolerance and a possible non-specific contribution of macromolecular crowding to cross-tolerance. Theoretical Biology and Medical Modelling, 2013, 10, 55.	2.1	10
299	SnapShot: Chronic Lymphocytic Leukemia. Cancer Cell, 2014, 26, 770-770.e1.	16.8	10
300	Interrupting Neuronâ€"Tumor Interactions to Overcome Treatment Resistance. Cancers, 2020, 12, 3741.	3.7	10
301	A Holistic Perspective: Exosomes Shuttle between Nerves and Immune Cells in the Tumor Microenvironment. Journal of Clinical Medicine, 2020, 9, 3529.	2.4	10
302	Crucial role of non-coding RNAs in disease. Cancer Letters, 2018, 420, 127-128.	7.2	9
303	Profiling the circulating miRnome reveals a temporal regulation of the bone injury response. Theranostics, 2018, 8, 3902-3917.	10.0	9
304	When non-coding is not enough. Journal of Experimental Medicine, 2020, 217, .	8.5	9
305	Classic and targeted antiâ€leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications. Journal of Cellular and Molecular Medicine, 2020, 24, 7378-7392.	3.6	9
306	MicroRNAs in Myeloid Hematological Malignancies. Current Genomics, 2015, 16, 336-348.	1.6	9

#	Article	IF	Citations
307	Analysis of the circRNA and T-UCR populations identifies convergent pathways in mouse and human models of Rett syndrome. Molecular Therapy - Nucleic Acids, 2022, 27, 621-644.	5.1	9
308	EGFR gets in the way of microRNA biogenesis. Cell Research, 2013, 23, 1157-1158.	12.0	7
309	Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. OncoImmunology, 2016, 5, e1117739.	4.6	7
310	The noncoding <scp>RNA</scp> revolutionâ€”three decades and still going strong!. Molecular Oncology, 2019, 13, 3-3.	4.6	7
311	MicroRNAs in Leukemias: A Clinically Annotated Compendium. International Journal of Molecular Sciences, 2022, 23, 3469.	4.1	7
312	Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. Methods in Molecular Biology, 2016, 1402, 33-41.	0.9	6
313	Allele Frequencies of Variants in Ultra Conserved Elements Identify Selective Pressure on Transcription Factor Binding. PLoS ONE, 2014, 9, e110692.	2.5	6
314	Selection of a Nuclease-Resistant RNA Aptamer Targeting CD19. Cancers, 2021, 13, 5220.	3.7	6
315	Small gene, big number, many effects. Blood, 2012, 120, 240-241.	1.4	5
316	Welcome to the New Journal Non-Coding RNA!. Non-coding RNA, 2015, 1, 1-3.	2.6	5
317	When kissing (disease) counts. Blood, 2016, 127, 1947-1948.	1.4	5
318	From cell biology to immunology: Controlling metastatic progression of cancer via microRNA regulatory networks. OncoImmunology, 2016, 5, e1230579.	4.6	5
319	Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. Journal of the National Cancer Institute, 2020, 112, 266-277.	6.3	5
320	Viral Micro-RNAs Are Detected in the Early Systemic Response to Injury and Are Associated With Outcomes in Polytrauma Patients. Critical Care Medicine, 2022, 50, 296-306.	0.9	5
321	Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study. Cell Death and Disease, 2022, 13, .	6.3	5
322	MiR-sensing chemotherapy resistance in CLL. Blood, 2009, 113, 3652-3653.	1.4	3
323	The Role of MicroRNAs and Ultraconserved Non-Coding RNAs in Cancer. , 2014, , 435-447.		3
324	The interplay between lnRNAs, SNPs, and protein complexes - what does it mean for cancer metabolism?. Molecular and Cellular Oncology, 2016, 3, e1166308.	0.7	3

#	Article	IF	Citations
325	miRNA Expression Assays. , 2019, , 51-71.		3
326	Pyknon-Containing Transcripts Are Downregulated in Colorectal Cancer Tumors, and Loss of PYK44 Is Associated With Worse Patient Outcome. Frontiers in Genetics, 2020, 11, 581454.	2.3	3
327	How Does a Tumor Get Its Shape? MicroRNAs Act as Morphogens at the Cancer Invasion Front. Non-coding RNA, 2020, 6, 23.	2.6	3
328	Molecular aspects of medicine â€“ Editorial 2019. Molecular Aspects of Medicine, 2019, 70, 1-2.	6.4	2
329	Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment. Frontiers in Oncology, 2021, 11, 682129.	2.8	2
330	MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights. MicroRNA (Shariqah, United Arab Emirates), 2016, 5, 106-112.	1.2	2
331	Pseudogenes, RNAs and new reproducibility norms. ELife, 2020, 9, .	6.0	2
332	lncRNAs UC.145 and PRKG1-AS1 Determine the Functional Output of DKK1 in Regulating the Wnt Signaling Pathway in Gastric Cancer. Cancers, 2022, 14, 2369.	3.7	2
333	Principles of MicroRNA Involvement in Breast Cancer. Breast Diseases, 2011, 22, 238-243.	0.0	1
334	Beyond miRNAs: Role of Other Noncoding RNAs in Cancer. , 2014, , 247-264.		1
335	Drugâ€“MicroRNA Cross-Talk. , 2015, , 991-1016.		1
336	MiRNA Expression Assays. , 2015, , 45-70.		1
337	Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome. Journal of Visualized Experiments, 2016, , .	0.3	1
338	Measurement of miRNAs in Chronic Lymphocytic Leukemia Patient Samples by Quantitative Reverse Transcription PCR. Methods in Molecular Biology, 2019, 1881, 267-276.	0.9	1
339	Preface for GCC Special Issue on noncoding RNAs, noncoding DNAs, and genome editing. Genes Chromosomes and Cancer, 2019, 58, 189-190.	2.8	1
340	TNF-alpha releasing capacity of the whole blood drops after open total splenectomy, but increases after partial/subtotal or minimally invasive splenectomy. Acta Chirurgica Belgica, 2022, 122, 346-356.	0.4	1
341	JAM-ming miR-21. Cell Death and Differentiation, 2021, 28, 2837-2839.	11.2	1
342	MicroRNAs as Therapeutic Targets. , 2015, , 683-697.		1

#	Article	IF	Citations
343	CpG island hypermethylation go circular (RNA). Oncotarget, 2018, 9, 33052-33053.	1.8	1
344	microRNA in cancer: An overview. , 2022, , 21-28.		1
345	MicroRNAs and Other Non-Coding RNAs: Implications for Cancer Patients. , 2013, , 1-12.		0
346	Small silencing non-coding RNAs: cancer connections and significance. , 0, , 481-496.		0
347	Therapeutic Potential of microRNAs. , 2015, , 543-564.		0
348	Estrogen and breast cancer: can less mean more?. Cell Cycle, 2015, 14, 2197-2198.	2.6	0
349	MicroRNA Involvement in Intestinal Tumorigenesis. , 2015, , 169-188.		0
350	The Non-Coding RNA Journal Club: Highlights on Recent Papersâ€”6. Non-coding RNA, 2018, 4, 23.	2.6	0
351	New Insights into the Molecular Mechanisms of Long Non-coding RNAs in Cancer Biology. , 2019, , 85-113.		0
352	Profiling Long Non-coding RNA expression Using Custom-Designed Microarray. Methods in Molecular Biology, 2021, 2372, 43-51.	0.9	0
353	Effects of long non-coding RNAs on androgen signaling pathways in genitourinary malignancies. Molecular and Cellular Endocrinology, 2021, 526, 111197.	3.2	0
354	Tyrosine Kinases, microRNAs, Epigenetics: New Insights in the Mechanisms of Leukemogenesis. , 2018, , 11-25.		0
355	Diagnostic and Therapeutic MicroRNAs in Primary Myelofibrosis. Proceedings of the Singapore National Academy of Science, 2020, 14, 91-109.	0.1	0
356	Tumorigenesis-Related Long Noncoding RNAs and Their Targeting as Therapeutic Approach in Cancer. RNA Technologies, 2020, , 277-303.	0.3	0
357	RNA delivery for cancer gene therapy. , 2022, , 375-424.		0